PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Please watch the video for more information
days to go:
Expired
investment:
£964,550
Gunna Drinks is a company that manufactures and sells craft soft drinks, consisting of natural juices with less than 5% sugar and no artificial colours or flavours. They have outshone established competitors like Gingerella, Fentimans & FeverTree in taste tests, and its recipes draw inspiration from around the world. Gunna is stocked in major supermarkets and convenience stores across the UK such as Co-op, Sainsbury’s, Amazon, Ocado, and JD Wetherspoon. Gunna Drinks has experienced 85% revenue growth in 2019 and was overfunded by 78% in its last crowdfunding round. The company will utilise the investment to boost consumer marketing to drive rapid revenue growth and develop new products and flavours.
days to go:
Expired
investment:
£274,880
GUNNA Drinks is an award-winning craft soft drinks brand designed with a delicious character for safe less sugar 100% natural flavours and no nasty preservatives or colour. The company has sold over 750, 000 fans and made partners with Barilla, Hershey’s, Illy, and Reeses. The company has achieved a 44% revenue increase between Dec 2017-Jul 2018, and Dec 2018-Jul 2019. The investment proceeds will be used for consumer marketing, the company's growth with Euro Food Brands, and product development.
days to go:
Expired
investment:
£668,716
Richard Brendon is a prominent British design brand that values master craftspeople by creating a platform for contemporary and timeless tableware collections that challenge the expected. It has received extensive media coverage since 2013 including the FT and NY Times. The company has sold to more than 120 B2B customers in 15 countries. It has seen a growth of 75% since 2015 amounting to £2.5m sales to date and more than 3,000 orders delivered. Richard now plans to take his brand global. It has enjoyed a CAGR of 75% from 2015 to 2019, with revenue of £1.12m in 2019. The company plans on opening up new markets, creating four additional collections over the coming years to develop existing channels and territories.
days to go:
Expired
investment:
£250,350
Docandu is an innovative digital health platform designed both for patients & doctors, making digital healthcare accessible from anywhere. Docandu aims to be a key tech health service provider, starting from Greece, improving the existing national and private health care services. The global digital health market is estimated to be worth $536 Billion by 2025. To date, they have developed two separate apps for doctors and patients. They have also received an angel investment of 100,000 Euros and sponsorship of $25,000 from Microsoft. The company has initiated early-stage relationships with a couple of Greek public and private health entities. With the proceeds, they will execute their go-to-market strategy and make global health ID a reality, by expanding its affiliate network of doctors, health providers and public health systems.
days to go:
Expired
investment:
£70,900
nHouse is a disruptive housing company that builds beautiful eco-friendly homes offsite in the UK. It makes houses by using modular methods wherein individual parts of a house are constructed separately in a factory before being transported and assembled together at the building site. The company's houses have Buildoffsite Property Assurance Scheme (BOPAS) accreditation; they are mortgage friendly and have a 60-year structural warranty. They have a demand of 300,000 houses every year in the UK. Major UK newspapers like the FT, The Times, The Guardian, and The Sun have covered nHouse's work. In 2025, the company is aiming to generate a return for shareholders via either a listing or trade sale. The investment will support working capital to extend the runway of nHouse into 2021.
days to go:
Expired
investment:
£147,480
